Thyroid Cancer A Comprehensive Guide to Clinical Management

In a massive updating of the highly acclaimed Thyroid Cancer: A Comprehensive Guide to Clinical Management, Drs. Leonard Wartofsky, Douglas Van Nostrand, and an expert group of contributing authors present a wealth of new information and insights on every aspect of the etiology, pathogenesis, diagnosis, initial treatment, and long-term management of all varieties of thyroid cancer. Paramount to this new edition is a thorough treatment of the nuclear medical aspects of diagnosing and managing the thyroid cancer patient. This includes extensive discussion of isotopes, isotope uptake and scanning procedures, radioiodine ablation and dosimetry (with or without recombinant human TSH), stunning, octreotide and FDG-PET scanning, and various alternative imaging modalities. Additional highlights include management of the scan-negative and thyroglobulin-positive patient, ultrasound of the lymph nodes, local adjuncts to therapy of metastases, low iodine diets and cookbooks, future directions in therapy, and alternative therapies when traditional surgery and radioactive iodine fail.
Encyclopedic and definitive, Thyroid Cancer: A Comprehensive Guide to Clinical Management, Second Edition, offers clinical endocrinologists, nuclear medicine physicians, pathologists, oncologists, endocrine surgeons, and internists an authoritative guide to the optimal diagnosis and treatment of thyroid cancer today.

are new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Management marks the pub- own recommendations and approach. The reader is fo- cation of a markedly updated and expanded volume that warned that in many cases these approaches, albeit rooted covers all aspects of the etiology, pathogenesis, diag- sis, initial treatment, and long-term management of all in available data, may be empiric rather than based varieties of thyroid cancer. Like the first edition, it will upon clear-cut results of well-controlled clinical t- als. Nevertheless, controversial issues are examined serve as a valuable reference source for pathologists, and evidence-based recommendations are presented endocrine surgeons, endocrinologists, nuclear medicine when available. physicians, and oncologists. However, the biggest There are updated chapters on our current state change is that the second edition is significantly enlarged and expanded to encompass important and extensive of knowledge of the molecular changes in thyroid treatments of more topics related to nuclear medicine. cancer, molecular markers, and how targeted the- pies are being developed. New therapeutic trials of Nuclear medicine physicians and procedures play a key redifferentiation agents to restore the sodium iodide role in the management of thyroid cancer patients and in symporter when lacking and more traditional che- retrospect, a comprehensive discussion of topics related therapies are discussed, with referral sources listed for to that field was somewhat lacking in the first edition.